Deurali-Janta Pharmaceuticals Pvt. Ltd.

What Deurali-Janta Pharmaceuticals Pvt. Ltd. does

Deurali-Janta Pharmaceuticals Pvt. Ltd. (DJPL) is a Nepalese pharmaceutical manufacturer founded in 1989 and headquartered in Kathmandu. The company operates a WHO-GMP and ISO 9001/14001 certified production facility equipped with modern manufacturing machinery and analytical instruments, alongside eco-friendly storage systems. It markets over 200 pharmaceutical SKUs spanning anti-diabetics, anti-hypertensives, antibiotics, anti-epileptics, anti-depressants, NSAIDs, respiratory, dermatology, hepatoprotective, gastrointestinal, and nutritional supplement categories in dosage forms including tablets, capsules, syrups, creams, ointments, and injectables.

DJPL has positioned itself as a pioneer in the Nepalese industry, notably conducting the country's first domestic Phase-III clinical trial of Favipiravir in 2021, and continues to expand its CNS portfolio with neurology launches in 2024. Its go-to-market runs through seven therapeutic-area marketing divisions (Aarambha, Aarogyam, DIVISION-I, DIVISION-II, Divyam, Nirog, Suswasthya) supported by an in-house Sales Force Automation platform, targeting healthcare professionals (doctors, physicians) and ultimately the Nepalese patient population. The firm operates a dedicated International Business division to develop export opportunities beyond Nepal.

Revenue is generated primarily through one-time pharmaceutical product sales via domestic distribution channels; pricing is not publicly disclosed. The company is privately held with no disclosed funding rounds, no parent company, and no public listing. Supporting functions include dedicated Manufacturing, R&D, Quality Assurance, Regulatory Management, Engineering, Stores, Market Planning, Human Resources, and Information Technology departments.

Name

Deurali-Janta Pharmaceuticals Pvt. Ltd.

Legal name

Deurali-Janta Pharmaceuticals Pvt. Ltd.

Website

https://deuralijanta.com

Company type

Private

Founded year

1989

Operating status

Operating

Short description

Deurali-Janta Pharmaceuticals is a WHO-GMP and ISO-certified Nepalese manufacturer founded in 1989, producing 200+ generic pharmaceutical SKUs across multiple therapeutic categories and serving Nepalese healthcare professionals and patients through a seven-division field sales structure.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• WHO-GMP certified drugs
• Prescription therapeutics
• Pharmaceutical formulations

Headquarters

HQ city

Kathmandu

HQ country

Nepal

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical products including tablets, capsules, syrups, creams, ointments, and other dosage forms across multiple therapeutic categories including anti-diabetics, antibiotics, cardiovascular, dermatology, and pain management.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Deurali-Janta Pharmaceuticals manufactures and sells a broad portfolio of branded pharmaceutical formulations — tablets, capsules, syrups, creams, ointments, solutions, suspensions, and gels — across multiple therapeutic categories including anti-diabetics, anti-hypertensives, antibiotics, anti-epileptics, anti-depressants, NSAIDs, anticoagulants, respiratory, dermatology, hepatoprotectives, antifungals, antacids, and nutritional supplements. Products are produced at a WHO-GMP and ISO 9001 & 14001 certified facility and distributed in Nepal through seven dedicated therapeutic marketing divisions, with an International Business division for export expansion.

Product overview

Deurali-Janta Pharmaceuticals Pvt. Ltd. is a WHO-GMP and ISO 9001 & 14001 certified Nepalese pharmaceutical company with a state-of-the-art manufacturing facility. The company offers an extensive portfolio of over 200 pharmaceutical products across multiple therapeutic categories including anti-diabetics (CARBOTRAP, SPANBEC, SITAGLIP, EFFIMET), anti-hypertensives (TELTAN, RAMIP, DIPLAR, METOP, LOTAN), antibiotics (ZULID, PERIMOX, TRICEF, PERIFLOX), anti-epileptics (BRIVERA, EPICOS, LEFLONTIN), anti-depressants (SENOBIT, PROSUN), anti-inflammatory/NSAIDs (COXIPRO, NEPOFEN, NAPROBEST), anticoagulants (THROMBIPREV), respiratory medications (MONKAST, BETA-BM, VASODRYL), hepatoprotectives (UDCOL, HEPAPROT), nutritional supplements (FORTIPLEX, CALVIT, FEROFOLIC), antacids (NORMOGEL), and topical medications (SEPTIDINE, RETIDERM, ULTRASOL). The company markets through seven divisions: Aarambha, Aarogyam, DIVISION-I, DIVISION-II, Divyam, Nirog, and Suswasthya, offering tablets, capsules, syrups, creams, ointments, solutions, suspensions, and gels.

Differentiator

Problem solved

Functional benefit

Products and services

• CARBOTRAP (Empagliflozin) Empagliflozin 10 mg/25 mg tablet for Type-II diabetes treatment, offering protection beyond glycemic control. Targeted at prescribers treating type-II diabetes patients in Nepal.
• COXIPRO (Etoricoxib) Etoricoxib 60 mg/90 mg tablet for osteoarthritis, gout, ankylosing spondylitis, and rheumatoid arthritis with selective action reducing GI toxicity. Targeted at prescribers treating inflammatory joint and pain conditions.
• GRELOR (Ticagrelor) Ticagrelor 60 mg/90 mg tablet — the pioneer Nepalese-brand antiplatelet agent for cardiovascular protection. Targeted at cardiologists managing acute coronary syndrome and post-PCI patients.
• BETA-BM Syrup Terbutaline 2.5 mg + Bromhexine HCl 8 mg syrup for asthma, COPD, and bronchitis with bronchodilatory, mucolytic, and expectorant effects. Targeted at prescribers treating obstructive respiratory conditions.
• PANORMA-D Capsule Pantoprazole 40 mg + Domperidone 30 mg prolonged-release capsule for hyperacidity with reflux and nausea. Targeted at prescribers treating gastroesophageal reflux and dyspepsia.
• ONDATRON (Ondansetron) Ondansetron 2 mg/4 mg/8 mg tablet and syrup for nausea and vomiting treatment. Targeted at prescribers managing chemotherapy-induced, post-operative, or gastroenteritis-related nausea and vomiting.
• SENOBIT (Duloxetine) Duloxetine 20/30/60 mg delayed-release capsule for depression and anxiety, restoring serotonin and norepinephrine balance. Targeted at psychiatrists and prescribers managing mood and anxiety disorders.
• EPICOS (Lacosamide) Lacosamide 50 mg/100 mg film-coated tablet for partial-onset seizures and primary generalised tonic-clonic seizures. Targeted at neurologists managing epilepsy.
• BRIVERA (Brivaracetam) Brivaracetam 50 mg/100 mg tablet for partial-onset seizures with high and selective affinity for synaptic vesicle protein 2A (SV2A). Targeted at neurologists managing refractory partial epilepsy.
• PROSUN (Fluoxetine) Fluoxetine 10 mg/20 mg tablet for depression treatment. Targeted at psychiatrists and prescribers managing depression and related mood disorders.
• ZULID (Azithromycin) Azithromycin 250 mg/500 mg tablet and suspension for bronchitis, pneumonia, sinusitis, pharyngitis, tonsillitis, and otitis media. Targeted at prescribers treating common bacterial infections.
• PERIMOX (Amoxicillin) Amoxicillin 250 mg/500 mg capsules and dry syrup for respiratory tract and other bacterial infections. Targeted at prescribers for first-line antibiotic therapy.
• TRICEF (Cefixime) Cefixime 100 mg/200 mg/400 mg tablets and dry syrup for urinary tract, respiratory, and ENT infections. Targeted at prescribers treating bacterial infections across specialties.
• THROMBIPREV (Apixaban) Apixaban 2.5 mg/5 mg tablets for anticoagulation. Targeted at prescribers managing thromboembolic conditions requiring oral anticoagulation.
• SPANBEC (Glimepiride) Glimepiride 1 mg/2 mg/3 mg tablets and combinations with Metformin ER for Type-II diabetes. Targeted at prescribers managing type-II diabetes.
• TELTAN (Telmisartan) Telmisartan 20 mg/40 mg/80 mg tablets for hypertension. Targeted at prescribers managing hypertension and related cardiovascular risk.
• FORTIPLEX (Multivitamin) Multivitamin and mineral capsules, syrups, and drops. Targeted at consumers and prescribers for general nutritional supplementation.
• NORMOGEL (Antacid) Magnesium Hydroxide + Aluminium Hydroxide suspension for hyperacidity, peptic ulcer, and gastritis. Targeted at consumers and prescribers for symptomatic gastric relief.
• LEFLONTIN (Levetiracetam) Levetiracetam 250 mg/500 mg/750 mg tablets for epilepsy. Targeted at neurologists treating epilepsy.
• UDCOL (Ursodeoxycholic Acid) Ursodeoxycholic Acid 150 mg/300 mg tablets for cholestatic liver diseases and gallstones. Targeted at gastroenterologists/hepatologists treating biliary and hepatic conditions.
• RETIDERM (Tretinoin) Tretinoin 0.025%/0.05% gel for acne treatment. Targeted at dermatologists managing acne vulgaris.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Cipla Limited: Indian multinational generic pharmaceutical company with significant market presence in Nepal. Competes with DJPL across multiple therapeutic categories and operates a broader global portfolio.
• Aurobindo Pharma Limited: Large Indian generic manufacturer with broad therapeutic coverage including antibiotics, anti-epileptics, and cardiovascular products that directly overlap with DJPL's portfolio categories.
• Lupin Limited: Indian pharmaceutical major with strong generic portfolio in cardiovascular, anti-diabetic, and CNS segments that overlap with DJPL's core therapeutic areas.
• Sun Pharmaceutical Industries Ltd. India's largest pharmaceutical company by revenue with extensive generic portfolio across all major therapeutic categories including those served by DJPL. Significant Nepal market presence.

Direct peers

• Nepal Pharmaceuticals Lab Pvt. Ltd. One of Nepal's oldest pharmaceutical manufacturers with WHO-GMP certified facilities and a multi-therapeutic product portfolio. Highly comparable as a domestic Nepalese generic pharma peer.
• Time Pharmaceuticals Pvt. Ltd. Nepalese pharmaceutical manufacturer producing generic medicines across multiple therapeutic categories. Directly comparable as a domestic Nepalese peer with WHO-GMP manufacturing and broad portfolio strategy.

Regional players

• Square Pharmaceuticals PLC: Bangladesh's largest pharmaceutical company with WHO-GMP certified manufacturing and broad generic portfolio. Comparable emerging-market generic manufacturer expanding across South Asia.
• Beximco Pharmaceuticals Ltd. Leading Bangladeshi pharmaceutical exporter with WHO-GMP certification and broad therapeutic coverage. Comparable as a South Asian generic manufacturer pursuing export markets.
• Renata Limited: Bangladesh-based pharmaceutical company with animal health and human pharma divisions. Comparable as a regional South Asian generic manufacturer with similar scale and emerging market focus.
• ACME Laboratories Ltd. Bangladesh-based pharmaceutical manufacturer with diversified portfolio across therapeutic categories. Comparable as a regional South Asian generic manufacturer with export ambitions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/deurali-janta

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deurali-Janta Pharmaceuticals Pvt. Ltd.